Skip to main content
Terug
SGRY logo

Surgery Partners, Inc.

Datakwaliteit: 100%
Oversold
SGRY
NASDAQ Healthcare Medical - Care Facilities
€ 11,49
▼ € 0,36 (-3,04%)
Marktkapitalisatie: 1,49B
Dagbereik
€ 11,46 € 11,86
52-Weeksbereik
€ 11,45 € 24,60
Volume
750.764
50D / 200D Gem.
€ 14,62 / € 18,97
Vorige Slotkoers
€ 11,85

Quick Summary

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (633 peers)

Metriek Aandeel Sector Mediaan
P/E -19,1 0,2
P/B 0,9 2,8
ROE % -4,5 3,7
Net Margin % -2,4 3,9
Rev Growth 5Y % 10,4 9,7
D/E 2,4 0,2

Koersdoel Analisten

Hold
€ 18,85 +64.1%
Low: € 16,25 High: € 21,00
Forward K/W
28,49
Forward WPA
€ 0,42
WPA Groei (sch.)
+0,0%
Omzet Sch.
3,41B

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2029 € 0,85
€ 0,82 – € 0,90
 4,52B 1
FY2028 € 0,59
€ 0,57 – € 0,62
 4,09B 1
FY2027 € 0,49
€ 0,17 – € 0,90
 3,59B 6

Earnings Surprises

Last 8 quarters
Quarter Est. EPS Actual EPS Surprise
2026-03-02 € 0,30 € 0,12 -60,6%
2025-11-10 € 0,19 € 0,13 -31,6%
2025-08-05 € 0,16 € 0,17 +6,3%
2025-05-12 € 0,08 € 0,04 -50,0%
2025-03-03 € 0,38 € 0,44 +15,8%
2024-11-12 € 0,25 € 0,19 -24,0%
2024-08-06 € 0,21 € 0,21 0,0%
2024-05-07 € 0,07 € 0,10 +42,9%

Dividend History

Yield

0,00%

Payout Ratio

0,00%

Growth (3Y)

N/A

Growth (5Y)

N/A

No dividend history available.

Belangrijkste Punten

Revenue grew 10,43% annually over 5 years — strong growth
Debt/Equity of 2,35 — high leverage
Generating 195,60M in free cash flow
PEG of 0,47 suggests growth is underpriced
Revenue growth is decelerating — 1Y growth trails 5Y average by 4,19%
Capital efficient — spends only 2,38% of revenue on capex

Groei

Revenue Growth (5Y)
10,43%
Revenue (1Y)6,24%
Earnings (1Y)N/A
FCF Growth (3Y)-2,32%

Kwaliteit

Return on Equity
-4,45%
ROIC5,09%
Net Margin-2,35%
Op. Margin11,77%

Veiligheid

Debt / Equity
2,35
Current Ratio1,87
Interest Coverage1,43

Waardering

P/E Ratio
-19,09
Forward P/E28,49
P/B Ratio0,87
EV/EBITDA13,54
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 6,24% Revenue Growth (3Y) 9,82%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 10,43% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 3,31B Net Income (TTM) -77,90M
ROE -4,45% ROA -0,95%
Gross Margin 23,12% Operating Margin 11,77%
Net Margin -2,35% Free Cash Flow (TTM) 195,60M
ROIC 5,09% FCF Growth (3Y) -2,32%
Safety
Debt / Equity 2,35 Current Ratio 1,87
Interest Coverage 1,43
Dividends
Dividend Yield 0,00% Payout Ratio 0,00%
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -19,09 Forward P/E 28,49
P/B Ratio 0,87 P/S Ratio 0,45
PEG Ratio 0,47 Forward PEG N/A
EV/EBITDA 13,54 Fwd EV/EBITDA 9,03
Forward P/S 0,44 Fwd Earnings Yield 3,51%
FCF Yield 13,15%
Market Cap 1,49B Enterprise Value 5,27B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 3,31B 3,11B 2,74B 2,54B 2,23B
Net Income -77,90M -168,10M -11,90M -54,60M -70,90M
EPS (Diluted) -0,61 -1,33 -0,09 -0,59 -1,12
Gross Profit 765,00M 745,60M 647,50M 574,90M 491,40M
Operating Income 389,50M 348,80M 328,00M 345,20M 302,20M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 8,24B 7,89B 6,88B 6,68B 6,12B
Total Liabilities 4,72B 4,25B 3,51B 3,40B 3,82B
Shareholders' Equity 1,71B 1,79B 1,99B 2,00B 1,09B
Total Debt 4,02B 3,70B 3,06B 2,93B 3,29B
Cash & Equivalents 239,90M 269,50M 195,90M 282,90M 389,90M
Current Assets 1,15B 1,12B 895,00M 921,00M 946,10M
Current Liabilities 615,50M 624,40M 523,00M 493,40M 536,80M

Strategiescores

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
Growth Price/Sales Ratio Focus (Ken Fisher)
#329 of 628
34

Recente Activiteit

Ingestapt Price/Sales Ratio Focus (Ken Fisher)
Mar 24, 2026